| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10833139 | Molecular Genetics and Metabolism | 2015 | 6 Pages |
Abstract
Acute myeloid leukemia (AML) is a hematologic malignancy that is the most common type of acute leukemia diagnosed in adults and the second most common type in children. The overall survival is poor and treatment is associated with significant complications and even death. In addition, a significant number of patients will not respond to therapy or relapse. In this review, several new signaling proteins aberrantly regulated in AML are described, including CREB, Triad1, Bcl-2 family members, Stat3, and mTOR/MEK. Identifying more effective and less toxic agents will provide novel approaches to treat AML.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Kathleen M. Sakamoto, Steven Grant, Diana Saleiro, John D. Crispino, Nobuko Hijiya, Francis Giles, Leonidas Platanias, Elizabeth A. Eklund,